ArticleInvestigative ophthalmology & visual science2026
Exogenous Fusarium Endophthalmitis: Clinical Features, Treatment Modalities, and Visual Outcomes.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Aspergillus Endophthalmitis: Clinical Features, Treatment Modalities, and Visual Outcomes.Investigative ophthalmology & visual science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To characterize the clinical features, treatment modalities, and visual outcomes of culture-proven exogenous Fusarium endophthalmitis managed at a tertiary referral center. Methods: This retrospective, single-center, consecutive case series included 14 eyes of 14 patients with culture-proven exogenous Fusarium endophthalmitis treated between October 2014 and December 2025. Diagnosis was confirmed by positive intraocular (aqueous or vitreous) cultures. Clinical records were reviewed for demographics, presenting characteristics, treatment course, complications, and visual and intraocular pressure outcomes. Results: Median presenting best-corrected visual acuity (BCVA) was 2.40 logMAR (∼20/5000). Infection sources included trauma (7/14, 50%), anterior segment surgery (5/14, 36%), and contact lens-associated fungal keratitis (2/14, 14%). All eyes required combined antifungal therapy (topical, intravitreal, intracameral, and/or intrastromal with systemic treatment) and surgical intervention, including therapeutic penetrating keratoplasty (14/14, 100%) and vitrectomy (8/14, 57%). Median follow-up was 594 days. Median BCVA at last follow-up remained poor at 2.25 logMAR (∼20/3600), with four of 14 patients (29%) achieving ≥20/400 vision and three of 14 patients (21%) having light perception or no light perception. Complications occurred in 10 of 14 eyes (71%), most commonly ocular hypertension or secondary glaucoma (8/10, 80%) and retinal detachment (3/10, 30%). No eyes required enucleation or evisceration. Conclusions: Exogenous Fusarium endophthalmitis is a serious ocular infection requiring multimodal therapy and multiple surgical interventions, yet long-term visual outcomes remain poor. Early fungal recognition and prompt antifungal treatment may improve outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.